Proprietary Longevity Biomarker Platform, $45k Subscription Digital Health Business

$1.1M

Revenue

$1.1M

SDE

3.2x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access Access Unlimited Deals

Already a member? Sign in

Full Editorial Writeup

This is a 100% online biomedical technology business that sells an annual longevity and health monitoring subscription for $45,000 per client. The platform integrates seven areas of human biology (genetics, epigenetics, immunology, metabolism, neurology, biomedical imaging, and lab blood work) into a single unified assessment, then tracks biomarkers over time and alerts clients to significant changes. Clients are high-net-worth individuals acquired entirely through professional networks and referrals, which the seller claims produces a $0 customer acquisition cost.

The economics as presented are striking: roughly $1.08M in revenue against $1.08M in reported cash flow, which immediately signals that the "revenue" and "cash flow" figures are being conflated or that costs are being understated. The business runs lean with no employees, no physical locations, and no working capital needs. The owner personally spends about one hour per client per month on consultations, a role the listing suggests can be outsourced to hourly consultants.

The pitch leans heavily on the macro longevity story: a US longevity market projected to grow from $25.2B in 2024 to $61.5B by 2034, plus digital health expanding at a 13.67% CAGR. The real question for a buyer is whether this is a durable platform with proprietary defensibility or a thin consulting wrapper around a small, concentrated book of wealthy clients. At a 3.24x multiple on a sub-$1M earnings base, the price assumes the subscription model and the referral engine are real and transferable.

Why we like it

The revenue model is 100% annual subscription at a $45,000 average order value, which is the kind of high-ticket recurring base that compounds nicely if retention is real. Each renewed client throws off outsized contribution because there is no inventory, no COGS beyond consultant time, and no working capital drag.
Reported customer acquisition cost is effectively zero, with every client to date arriving through professional networking and referrals and the website still pulling 10,000 monthly visitors with no blog, ads, or social program. If a buyer layers even modest paid acquisition onto a proven $45k offer, the unit economics could be exceptional.
The business is genuinely asset-light and portable: no employees, no locations, no working capital, and an asset transfer that completes online in 2 to 3 days. For an operator who wants a clean, remotely-run cash machine without a payroll or lease, the operational footprint is about as simple as it gets.
Growth optionality is broad and untouched, including B2B licensing to longevity clinics, wellness groups, insurers, and corporate wellness buyers, plus international expansion into the Middle East and Europe with no physical buildout required. None of this upside is priced in, since no formal marketing has ever been attempted.

How to improve it

Stand up a real demand engine in the first 90 days using SEO, educational content, and direct outreach to high-net-worth prospects and their advisors. The business has never run marketing, so even a basic funnel against a proven $45k offer should produce measurable pipeline quickly.
Launch a B2B licensing motion targeting longevity clinics, concierge medical groups, and corporate wellness providers on monthly or annual fees. This converts the proprietary platform from a one-client-at-a-time consulting model into scalable software revenue with higher margins and less founder dependency.
Introduce tiered pricing and a monthly billing option to widen the top of the funnel below the $45k price point. A lower entry tier captures prospects who balk at a $45,000 annual commitment while preserving the premium flagship product for the highest-value clients.
Replace the founder's one-hour-per-client monthly consultation with a trained pool of hourly or contract clinicians and a documented protocol. This removes key-person risk, protects margins, and makes the earnings defensible under diligence and at exit.
Build and instrument a real retention and renewal process, since the entire thesis rests on clients renewing a $45k annual term. Add health-check cadences, outcome reporting, and proactive account management to lift renewal rates and surface churn risk early.
Pursue international expansion into high-income markets like the Gulf and Western Europe with localized positioning and compliant data handling. Since no physical buildout is needed, the incremental cost is marketing and regulatory review rather than capex.

Diligence notes

The revenue of roughly $1.08M and cash flow of roughly $1.08M are nearly identical, which is a red flag that costs are understated or the two figures are conflated. Reconcile the actual P&L line by line, because the listing separately cites "$809k Annual Profit," and these numbers do not agree with each other.
Verify the actual subscriber count, the per-client renewal history, and customer concentration. At $45,000 per client, a book of roughly 20 to 25 clients drives the whole business, so losing even a handful of accounts materially changes the earnings and the price you should pay.
Pressure-test the "proprietary tech" and "no consultant needed" claims against the fact that the founder built the entire platform and personally delivers consultations. Confirm what intellectual property transfers, whether any third-party data, lab, or imaging dependencies exist, and how the system actually runs without the founder.
Scrutinize regulatory and liability exposure, since the platform handles genetics, imaging, blood work, and personalized health guidance. Understand HIPAA and data-privacy obligations, the line between wellness guidance and regulated medical advice, and what licensing or malpractice risk a buyer inherits.
Validate the referral-driven, zero-CAC claim by identifying exactly where clients come from and whether those referral relationships are tied to the founder personally. If the pipeline depends on the seller's network, the $0 acquisition cost may evaporate after closing.
Confirm the business's age and track record, since years in business is listed as unknown. A high multiple on a short operating history with few renewals cycles is far riskier than the same numbers from a seasoned book with proven multi-year retention.

Source

Originally listed on BizBuySell. View original listing →